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Ubiquitin-dependent degradation of active Src
Yaron Hakak and G. Steven Martin
Signaling by members of the Src family of protein
tyrosine kinases, such as Src and Fyn, is important in
many biological responses, including gene
transcription, cell-cycle progression, and cell adhesion
and spreading [1,2]. Unregulated Src kinase activity has
been implicated in the progression of colon cancer and
transformation of cultured cells [3–6]. Thus, precise
regulation of Src activity is critical for normal cell
growth. Src kinase activity is downregulated by the
carboxy-terminal Src kinase (Csk), a tyrosine kinase
that phosphorylates a conserved tyrosine residue in the
carboxy-terminal tail of Src [7,8]. When phosphorylated,
this tyrosine residue mediates an intramolecular
interaction that results in a ‘closed’ or inactive
conformation [1,2,9,10]. Here, we report that loss of csk
resulted in a reduction in the abundance of the Src and
Fyn proteins, which could be restored by reintroducing
catalytically active Csk. The effect of Csk on Src
expression was not due to an increase in Src message,
but to stabilization of the Src protein. Inhibition of
proteasome activity also increased the level of Src
protein in csk-deficient cells. Src was found to be
ubiquitinated, and activation of Src increased the extent
of polyubiquitination. Thus, ubiquitin–proteasome-
dependent degradation represents an additional
mechanism by which active Src can be downregulated.
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Results and discussion
In studying the regulation of Src by Csk, we and others
have noticed a correlation between Src protein levels and
expression of Csk [11,12]. To determine whether Csk
could directly affect the level of Src expression, we
infected csk-deficient cells with a retroviral vector encod-
ing either wild-type Csk or a catalytically inactive mutant
in which amino-acid residue 222 was mutated to arginine
(Csk R222); csk–/– cells infected with empty vector were
used as controls. The activity of endogenous Src family
kinases was assessed by immunoblot analysis of cell
lysates with anti-phosphotyrosine antibody. As reported
previously [13], the kinase activity of Src family members
was strongly inhibited by expression of wild-type Csk, but
not by expression of Csk R222 (Figure 1b). The levels of
Src and Fyn were determined by immunoblot analysis of
cell lysates (Figure 1b). When wild-type Csk was
expressed in csk–/– cells, the cells had over fivefold higher
Src protein levels and over fourfold higher Fyn protein
levels than the same cells infected with the empty vector
(Figure 1a); csk–/– cells expressing Csk R222 contained
only slightly elevated levels of Src and Fyn proteins. To
further characterize the effects of Csk on the level of Src
protein, csk–/– clones expressing comparable levels of wild-
type Csk or Csk R222 were generated by transfection. Src
protein levels were approximately threefold higher in
clones expressing wild-type Csk than in control clones
transfected with empty vector or those expressing Csk
R222 (Figures 1c,d). Thus, catalytically active Csk
induces an increase in the abundance of Src and Fyn
protein, whereas catalytically inactive Csk induces at most
a small increase. These data suggest that inactivation of
Src and Fyn by Csk protects them from some mechanism
that downregulates their abundance.
To determine whether the regulation of Src protein
expression occurs at the transcriptional level, we analyzed
the levels of src and fyn mRNA in csk–/– cells expressing
wild-type Csk, Csk R222, or empty vector. Neither wild-
type Csk nor Csk R222 expression affected the level of src
message (Figure 1e). The level of fyn mRNA was also
unaffected by Csk expression (data not shown). Thus,
downregulation of Src protein levels occurs through a
post-transcriptional mechanism.
A possible explanation for the effect of Csk expression on
Src abundance is that phosphorylation by Csk affects the
turnover rate of the molecule. Pulse-chase experiments
were therefore performed to determine the stability of Src
protein in csk–/– cells expressing empty vector or wild-type
Csk (Figure 2a). Similar levels of pulse-labeled Src protein
were detected in the two cell types, indicating that Csk
did not affect the rate of synthesis of Src. The half-life of
Src in csk–/– cells re-expressing wild-type Csk was 12 hours
(Figure 2b). In csk–/– cells expressing empty vector,
however, Src had a more rapid turnover rate, with an
approximately 4.5 hour half-life. The levels of
[35S]methionine label incorporated and the rates of
turnover of total cellular protein were similar in the two
cell types, indicating that the effect of Csk on Src turnover
was not due to a general effect on the turnover of cellular
proteins (Figure 2c). Thus, inactivation of Src by Csk pro-
tects Src from degradation.
In eukaryotes, regulated intracellular proteolysis generally
involves the ubiquitin–proteasome pathway. To deter-
mine whether the degradation of Src was proteasome-
dependent, csk–/– cells were treated for 4 hours with the
proteasome inhibitor MG132. The level of Src protein
increased approximately twofold in MG132-treated cells,
suggesting that Src protein is a target of proteasome-
dependent degradation (Figure 2d). At later times, the
MG132-treated csk–/– cells underwent apoptosis (data not
shown), precluding analysis of Src accumulation over a
longer time period. The effect of Csk on the level of Src
protein was specific, as the level of the tumor suppressor
protein p53, a target of the proteasome pathway, was
similar in csk–/– cells expressing empty vector and in those
re-expressing wild-type Csk  (Figure 2e).
Proteins that are covalently conjugated to the 76 amino
acid ubiquitin molecule are recognized as targets for
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Figure 1
Effect of Csk expression on levels of Src and
Fyn protein and src RNA. (a) Quantitation of
Src and Fyn protein levels from
(b) immunoblot analysis of lysates of infected
csk–/– cells expressing empty vector (lane 1),
kinase-inactive Csk (Csk R222, lane 2), or
wild-type Csk (Csk WT, lane 3) using
antibodies directed against Src, Fyn, Csk and
phosphotyrosine (pTyr). (c) Quantitation of Src
protein levels from (d) immunoblot analysis of
lysates of transfected csk–/– cells expressing
empty vector (clones 1,2), Csk R222 (clones
8,11), or Csk WT (clones 28,17) using
antibodies directed against Src and Csk.
(e) Northern blot analysis of total RNA from
csk–/– cells expressing empty vector,
Csk R222, or Csk WT; src–/– cells were used
as a negative control. The membrane was
probed with radiolabeled cDNAs encoding Src
and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), which detected
bands at 3.8 kb and 1.3 kb, respectively.
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Figure 2
Regulation of Src turnover by Csk. (a) Cells
(csk–/–) expressing empty vector or Csk WT
were metabolically labeled with
[35S]methionine and then transferred to non-
radioactive medium. At the indicated times of
chase, cells were lysed and Src
immunoprecipitated. Samples were resolved
by SDS–PAGE and radiolabeled Src
detected by autoradiography. The first lane on
the left shows a parallel immunoprecipitate
from lysates of src–/– cells. (b,c) Levels of
(b) radiolabeled Src protein and (c) total
radiolabeled cell protein in csk–/– cells
expressing empty vector (closed squares) or
Csk WT (open circles) were quantitated by
phosphorimager analysis or scintillation
counting of trichloroacetic-acid-precipitated
cell lysates. (d) Immunoblot analysis with anti-
Src antibody of lysates of csk–/– cells
expressing empty vector that were treated for
4 h with either dimethylsulfoxide (DMSO) or
40 µM MG132. (e) Immunoblot analysis with
anti-p53 antibody of lysates of csk–/– cells
expressing empty vector or Csk WT.
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degradation by the proteasome. The conformation and
phosphorylation state of substrate proteins have been
implicated as targeting signals for the ubiquitination
machinery [14]. To determine whether Src is ubiquiti-
nated and whether the activation state of Src affects the
extent of ubiquitination, we examined Src immunopre-
cipitates for the presence of Src–ubiquitin conjugates.
Human embryonic kidney 293 cells were transiently
cotransfected with a construct expressing hemagglutinin
(HA)-tagged ubiquitin (HA–ubiquitin), together with
DNA encoding either wild-type Src, activated Src (in
which the regulatory Tyr527 residue has been mutated
to phenylalanine; Src Y527F), or a Src molecule that is
conformationally ‘open’ as a result of the Y527F muta-
tion but catalytically inactive as a result of mutation of
the Lys295 residue to arginine (Src K295R Y527F). Src
was immunoprecipitated, and the immunoprecipitates
examined by immunoblotting with anti-Src and anti-HA
antibodies (Figure 3). 
Overexpression of wild-type Src in the presence of
HA–ubiquitin resulted in the formation of an elec-
trophoretically-retarded form of Src with an apparent
molecular weight of ~68 kDa (compare lanes 2 and 3).
This electrophoretically retarded form of Src had the
same mobility as a band in the blot probed with anti-HA
antibody and presumably represents a monoubiquiti-
nated form of Src (compare lanes 2 and 3 with lanes 7
and 8). As the monoubiquitinated form was not seen with
Src alone, its formation could reflect HA–ubiquitin over-
expression, and it may not be on the pathway to polyu-
biquitination. Coexpression of HA-ubiquitin with
activated Src (Src Y527F), resulted in the formation of
the same electrophoretically-retarded form of Src at
~68 kDa (lanes 4 and 9). Src Y527F was also found in
polyubiquitinated forms (compare lanes 4 and 9 with
lanes 3 and 8), indicating that activated Src is more
extensively ubiquitinated than the wild-type form.
Expression of conformationally open but catalytically
inactive Src, Src K295R Y527F, did not result in the for-
mation of polyubiquitinated species (lanes 5 and 10).
Therefore, an open conformation is not sufficient for Src
polyubiquitination, whereas catalytic activity is required.
This would suggest that Src either activates a signaling
pathway that targets it for degradation, or that autophos-
phorylation (there is a known autophosphorylation site at
Tyr416 in Src) is required for recognition of the molecule
by the ubiquitinating machinery. It will be difficult to
differentiate between these possibilities as autophospho-
rylation at Tyr416 is required for complete c-Src catalytic
activity [1]. These data indicate that ubiquitination is
promoted by Src activation.
We conclude that Src kinase activity can be downregu-
lated, not only by inactivation by Csk, but also by ubiqui-
tin–proteasome-dependent degradation. Phosphorylation
by Csk induces a conformational change in Src through
intramolecular interactions that convert it from the open
to the closed conformation. Activated Src molecules that
escape this mode of regulation are susceptible to degrada-
tion by ubiquitin–proteasome-dependent degradation.
Phosphorylation by Csk and consequent folding of Src
into the inactive form may directly protect Src from being
recognized by the ubiquitination machinery. Another pos-
sibility is that activated Src may itself activate the machin-
ery responsible for its own ubiquitination. Irrespective of
the mechanism involved, downregulation of active Src by
degradation represents an additional mechanism by which
the activity of Src family members can be regulated. Ele-
vated levels of Src protein are found in many colon carci-
nomas [4] with mutational activation also occurring in
advanced metastatic forms [5]. Thus the ligase responsible
for Src ubiquitination represents a potential tumor sup-
pressor, and a defect in ubiquitin–proteasome-dependent
degradation of Src might potentiate the development of
some carcinomas.
Supplementary material
Supplementary material including additional methodological details is
available at http://current-biology.com/supmat/supmatin.htm.
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Figure 3
Ubiquitination of Src. Human embryonic kidney 293 cells were
transfected as indicated with a construct expressing HA–ubiquitin
together with empty vector or DNA encoding either wild-type Src, Src
Y527F, or Src K295R Y527F. Src was immunoprecipitated (IP) and
samples subject to immunoblot analysis with anti-Src (left) or anti-HA
(right) antibodies.
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Supplementary materials and methods
Plasmids and antibodies
B. Howell and J. Cooper (Fred Hutchinson Cancer Research Center,
Washington) provided pLXSH, pLXSH-Csk R222 and pLXSH-Csk
WT. A. DeFranco (U.C. San Francisco) provided pUC18-src and
pSM-fyn. G. Firestone (U.C. Berkeley) provided pUC18-GAPDH
which encodes glyceraldehyde-3-phosphate dehydrogenase. S.
Courtneidge (Sugen, Inc., California) provided pSGT c-Src and c-
Src Y527F. S. Taylor (Cornell U., New York) provided pcDNA3-Src
K295R Y527F. D. Bohmann (EMBL, Germany) provided pMT 123,
which encodes hemagglutinin (HA)-tagged ubiquitin. Src antibody
2–17 was purified from tissue culture supernatant. The following
antibodies were purchased: anti-Fyn and anti-Csk antibodies (Santa
Cruz Biotechnology), anti-phosphotyrosine monoclonal antibody
4G10 (Upstate Biotechnology), anti-p53 antibody (Oncogene
Research Products) and anti-HA monoclonal antibody 3F10
(Boehringer Mannheim).
Cell culture and transfections 
B. Howell and J. Cooper provided csk–/– cells infected with the retro-
viral vector pLXSH or with the same vector encoding wild-type Csk
or kinase-inactive Csk (Csk R222) as described elsewhere [S1];
csk–/– clones were generated by transfecting csk–/– cells with the
Csk constructs by the calcium phosphate method followed by selec-
tion with 50 µg/ml hygromycin. P. Soriano (Fred Hutchinson Cancer
Research Center, Washington) provided src–/– cells. Cells were
grown in a mixture of Dulbecco’s modified Eagle medium (DMEM) (1
part) and Ham’s F-10 nutrient mixture (2 parts) supplemented with
10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml strepto-
mycin; csk–/– cell lines were kept under constant selection with
50 µg/ml hygromycin and lysed when 80–90% confluent. Where
indicated, csk–/– cells were incubated with DMSO or 40 µM MG132
(Calbiochem) for 4 h. Human embryonic kidney 293 cells were
plated 20–24 h before transfection. Cells were transiently trans-
fected by the calcium phosphate method with the indicated Src and
HA–ubiquitin constructs.
Immunoprecipitations and immunoblot analysis
Cells (csk–/–) were lysed in RIPA buffer, which contains 10 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.05% SDS, 1% Nonidet P-40, 1%
sodium deoxycholate, 1 mM EDTA, 2 mM Na3VO4, protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 µM benzamidine,
5 µM phenanthroline and 0.5 µg/ml antipain, leupeptin, pepstatin,
aprotinin and chymostatin). Lysates were cleared by centrifugation
(14,000 × g for 10 min) and resolved by SDS–PAGE. Immunoblot
analysis was then performed with antibodies directed against Src,
Fyn, Csk and phosphotyrosine, and relative protein levels quantitated
by scanning densitometry with NIH Image software. Quantitated
results are the average and standard deviation of three independent
experiments. Human embryonic kidney 293 cells were lysed in RIPA
buffer 40 h post-transfection. Lysates were cleared and adjusted to
equal protein concentrations (3.0 mg/ml). Src was immunoprecipi-
tated with anti-Src antibody. The immunoprecipitates were washed
four times with lysis buffer and resolved by SDS–PAGE on an 8.5%
polyacrylamide gel. Immunoblot analysis was then performed with
anti-Src and anti-HA antibodies. 
Northern blot analysis
RNA was purified from csk–/– and src–/– cells with the Qiagen
RNeasy Total RNA kit for northern blot analysis. Hybridization probes
were prepared from the 1.8 kb full-length murine c-src cDNA excised
from pUC18-src, the 2.3 kb murine fyn cDNA excised from pSM-fyn,
and a 0.5 kb fragment of GAPDH cDNA (as a control for RNA loading)
excised from pUC18-GAPDH. 
Pulse-chase experiments 
Cells (csk–/–) were washed with methionine-free DMEM (Gibco BRL)
supplemented with 10% dialyzed fetal calf serum. Cells were then
incubated for 2 h with the wash medium containing 500 µCi/ml Tran
35S-Label (ICN). Cells were subsequently washed and incubated in
normal growth medium. At the indicated chase times, cells were lysed
in RIPA buffer and lysates prepared as described above. Lysates were
precleared with protein A/G Plus-agarose beads (Santa Cruz Biotech-
nology) for 1 h and adjusted to equal protein concentrations
(1.0 mg/ml). Src was immunoprecipitated and samples resolved by
SDS–PAGE on a 12.5% acrylamide, low bis (0.07%) gel. Relative
levels of labelled Src were quantitated by phosphorimager analysis.
Quantitation of total radiolabel in cell protein was performed by spot-
ting lysates from pulse-chased cells on 3MM filter paper followed by
trichloroacetic acid washes and scintillation counting. Results are the
average and standard deviation of two independent experiments.
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